NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

CompletedPhase 1

Sponsor: Regeneron Pharmaceuticals

Conditions: Healthy Volunteers

Interventions: REGN3500, Placebo

Countries: Belgium

The primary objective of this study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN3500 in healthy adult males and females

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Body Mass Index\</= 33 kg/m2
* In good health based on medical history, physical examination, vital signs, and laboratory testing
* Normal electrocardiogram (ECG) and blood pressure
* Able to comply with clinic visits and study-related procedures
* Able to sign an informed consent

Exclusion Criteria:

* Significant abnormalities in hematology, clinical chemistry, urinalysis, medical history
* Current smoker or recent history (within 3 months)
* History of tuberculosis, HIV, or hepatic disease
* Known sensitivity to doxycycline or other ingredients of study drug
* History of multiple/severe allergies
* Pregnant or breastfeeding women, or not currently using adequate contraception
* Participation in another investigational drug study within 4 weeks

Locations (1)

Ghent, Belgium